These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 19268185)

  • 1. [Expert opinion on APAP (prolonged action atypical antipsychotic agents). Current status of recommendations for treatment with an APAP].
    Buis C; Gourion D; Vaiva G
    Encephale; 2009 Jan; Suppl 3():S91-5. PubMed ID: 19268185
    [No Abstract]   [Full Text] [Related]  

  • 2. [Expert opinion on APAP (prolonged action atypical antipsychotic agents). How to make the decision to resort to an APAP)].
    Chéreau I; Gorwood P; Mouchabac S
    Encephale; 2009 Jan; Suppl 3():S97-100. PubMed ID: 19268186
    [No Abstract]   [Full Text] [Related]  

  • 3. [Expert opinion on APAP (prolonged action atypical antipsychotic agents). How to prescribe an APAP?].
    Dassa D; Lacambre M; Vacheron MN
    Encephale; 2009 Jan; Suppl 3():S109-13. PubMed ID: 19268179
    [No Abstract]   [Full Text] [Related]  

  • 4. [Expert opinion on APAP (prolonged action atypical antipsychotic agents). What are the limiting factors in resort to an APAP and how to overcome them].
    Canceil O; Limosin F; Passerieux C
    Encephale; 2009 Jan; Suppl 3():S101-7. PubMed ID: 19268178
    [No Abstract]   [Full Text] [Related]  

  • 5. [Expert opinion on APAP (prolonged action atypical antipsychotic agents). Position of Canadian psychiatry].
    Stip E
    Encephale; 2009 Jan; Suppl 3():S115-8. PubMed ID: 19268180
    [No Abstract]   [Full Text] [Related]  

  • 6. [Expert opinion on APAP (prolonged action atypical antipsychotic agents). How to evaluate the quality of observations].
    Benoit M; Pon J; Zimmermann MA
    Encephale; 2009 Jan; Suppl 3():S87-90. PubMed ID: 19268184
    [No Abstract]   [Full Text] [Related]  

  • 7. [Expert opinion on APAP (prolonged action atypical antipsychotic agents). Position of the pharmacologist. From neuroleptics to non-neuroleptic antipsychotics].
    Costentin J
    Encephale; 2009 Jan; Suppl 3():S119-22. PubMed ID: 19268181
    [No Abstract]   [Full Text] [Related]  

  • 8. [Expert opinion on APAP (prolonged action atypical antipsychotic agents). Foreword].
    Guelfi JD; Costentin J; Terra JL
    Encephale; 2009 Jan; Suppl 3():S85-6. PubMed ID: 19268183
    [No Abstract]   [Full Text] [Related]  

  • 9. [Expert opinion on APAP (Prolonged action atypical antipsychotic agents). Conclusion].
    Guelfi JD
    Encephale; 2009 Jan; Suppl 3():S123-4. PubMed ID: 19268182
    [No Abstract]   [Full Text] [Related]  

  • 10. Observations on the use of long-acting depot neuroleptic injections in the maintenance therapy of schizophrenia.
    Johnson DA
    J Clin Psychiatry; 1984 May; 45(5 Pt 2):13-21. PubMed ID: 6143743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review of treatments that can ameliorate nonadherence in patients with schizophrenia.
    Kane JM
    J Clin Psychiatry; 2006; 67 Suppl 5():9-14. PubMed ID: 16822091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical guidelines: Dosing and switching strategies for long-acting risperidone.
    Marder SR; Conley R; Ereshefsky L; Kane JM; Turner MS
    J Clin Psychiatry; 2003; 64 Suppl 16():41-6. PubMed ID: 14680418
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment compliance of outpatients with schizophrenia: patient's attitudes, demographic, clinical and therapeutic variables.
    Stanković Z; Britvić D; Vuković O; Ille T
    Psychiatr Danub; 2008 Mar; 20(1):42-52. PubMed ID: 18376330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Subjective well-being under antipsychotic treatment and its meaning for compliance and course of disease].
    Naber D; Lambert M; Karow A
    Psychiatr Prax; 2004 Nov; 31 Suppl 2():S230-2. PubMed ID: 15586315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors which can make patients difficult to treat.
    Kane JM
    Br J Psychiatry Suppl; 1996 Dec; (31):10-4. PubMed ID: 8968650
    [No Abstract]   [Full Text] [Related]  

  • 16. Strategies for dosing and switching antipsychotics for optimal clinical management.
    Buckley PF; Correll CU
    J Clin Psychiatry; 2008; 69 Suppl 1():4-17. PubMed ID: 18484804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Guidelines on long-acting injectable atypical antipsychotics for first-episode schizophrenia].
    Azorin JM
    Encephale; 2013 Sep; 39 Suppl 2():S121-3. PubMed ID: 24084422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [CUtLASS 1 - Increasing disillusion about 2nd generation neuroleptics].
    Steinert T
    Psychiatr Prax; 2007 Jul; 34(5):255-7. PubMed ID: 17607643
    [No Abstract]   [Full Text] [Related]  

  • 19. Relapse prevention and recovery in the treatment of schizophrenia.
    Schooler NR
    J Clin Psychiatry; 2006; 67 Suppl 5():19-23. PubMed ID: 16822093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ideal and reality of neuroleptic relapse prevention.
    Kissling W
    Br J Psychiatry Suppl; 1992 Oct; (18):133-9. PubMed ID: 1356363
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 20.